Company profile

Bicara Therapeutics Inc.

Pipeline1 asset

ficerafusp alfaBCA101 / EGFR/TGF-β / bifunctional EGFR-directed monoclonal antibody bound to a human TGF-β ligand trap / Oncology
1L recurrent/metastatic HPV-negative head and neck squamous cell carcinomaPhase 2/3ongoinggloballate-line MSS RAS wild-type metastatic colorectal cancerPhase 1/1benrolling expansion cohort

No recent headlines yet.

New company coverage will appear here as soon as it is picked up.